ArticleBMC infectious diseases2025
Mpox surveillance in endemic regions: a scoping review of trends, challenges, and recommendations.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMpox continues to pose a significant public health threat in endemic regions of Africa, particularly with the emergence of new viral clades and continuous human-to-human transmission. This scoping review assesses existing Mpox surveillance systems in endemic parts of Africa, highlighting key trends, challenges, and opportunities for improvement.
methodsA scoping review was conducted following the PRISMA-ScR guidelines. Five electronic databases (PubMed, Scopus, Embase, Web of Science, and Cochrane Library) were searched in September 2025. Studies conducted in the WHO African Region that described, evaluated, or implemented Mpox laboratory surveillance systems were included. Eligible articles underwent screening and data extraction using the Covidence software. Data extracted from the reviewed studies were charted according to surveillance structures, diagnostic methods, reporting strategies, and implementation challenges.
results24 studies were included for review, predominantly from Central and West Africa, particularly the Democratic Republic of Congo (DRC), Nigeria, Cameroon, and the Central African Republic (CAR). Surveillance systems varied in scope and design, ranging from passive and active national frameworks to cross-border monitoring. Diagnostic approaches commonly relied on polymerase chain reaction (PCR) testing, though limitations in laboratory infrastructure and delayed specimen transport hindered timely case confirmation. Key challenges identified include deficits in diagnostic capacity, misclassification of disease based on symptoms, and limited follow-up investigations. Structural barriers such as poor infrastructure, healthcare worker shortages, and conflict-related disruptions further weakened Mpox surveillance. Stigma and lack of community awareness contributed to underreporting. Additionally, the circulation of multiple Mpox viral clades and frequent cross-border transmission complicated outbreak detection and containment.
conclusionWhile Mpox surveillance capacity has improved modestly, major structural and systemic challenges persist. Strengthening Mpox surveillance in endemic regions requires a multi-level strategy to ensure timely detection and containment of future outbreaks. CLINICAL TRIAL NUMBER: Not applicable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.